Milestone Pharmaceuticals (NASDAQ:MIST) Receives Buy Rating from HC Wainwright

Milestone Pharmaceuticals (NASDAQ:MIST)‘s stock had its “buy” rating reissued by equities researchers at HC Wainwright in a research note issued on Friday,Benzinga reports. They currently have a $25.00 target price on the stock.

Milestone Pharmaceuticals Stock Performance

Shares of MIST traded down $1.33 during midday trading on Friday, reaching $0.92. 28,490,728 shares of the stock were exchanged, compared to its average volume of 653,740. The stock’s 50 day simple moving average is $2.02 and its 200 day simple moving average is $1.83. The company has a market cap of $49.25 million, a P/E ratio of -1.17 and a beta of 1.83. Milestone Pharmaceuticals has a twelve month low of $0.75 and a twelve month high of $2.75. The company has a quick ratio of 15.40, a current ratio of 15.40 and a debt-to-equity ratio of 2.18.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in MIST. Jones Financial Companies Lllp grew its position in Milestone Pharmaceuticals by 1,000.0% during the fourth quarter. Jones Financial Companies Lllp now owns 11,000 shares of the company’s stock worth $26,000 after buying an additional 10,000 shares in the last quarter. PVG Asset Management Corp bought a new position in shares of Milestone Pharmaceuticals in the third quarter worth $46,000. Northern Trust Corp raised its stake in Milestone Pharmaceuticals by 112.6% in the fourth quarter. Northern Trust Corp now owns 58,108 shares of the company’s stock valued at $137,000 after purchasing an additional 30,772 shares in the last quarter. Toronto Dominion Bank acquired a new position in Milestone Pharmaceuticals in the fourth quarter valued at about $1,770,000. Finally, Cubist Systematic Strategies LLC bought a new stake in Milestone Pharmaceuticals during the fourth quarter worth about $73,000. 86.18% of the stock is owned by institutional investors.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.